Answers are grounded in this paper and cite their sources.
Background Histotripsy is an emerging noninvasive, nonthermal ablative therapy recently introduced for the treatment of hepatic malignancies. This systematic review evaluated the efficacy and safety of histotripsy for primary and secondary liver tumors. Methods PubMed and Scopus were searched from inception through August 2026 in accordance with PRISMA guidelines. Search terms included combinations of subject headings and keywords such as “histotripsy,” “hepatic,” and “metastases.” Results Ten clinical studies published between 2022 and 2026 met inclusion criteria. Study populations included hepatocellular carcinoma and metastases from colorectal, neuroendocrine, pancreatic, breast, and other malignancies. Technical success ranged from 68.8% to 100%, although definitions varied across studies. Early treatment efficacy and local control were generally high among successfully treated tumors, with several studies reporting rates exceeding 90%. Longer-term oncologic data were limited by heterogeneous imaging criteria, treatment intent, and patient populations. Major complications were uncommon, although vascular thrombosis and acute kidney injury emerged as potential safety concerns. Conclusions Current evidence supports the technical feasibility and short-term efficacy of hepatic histotripsy. However, standardized outcome definitions, longer follow-up, and comparative studies are needed to establish its durability and role relative to existing liver-directed therapies.
No takes yet. Share an insight, caveat, or question.
Roberts et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: